Clinical trials: Interstitial Fibrosis
Pulmonary Fibrosis
A Study in People With Pulmonary Fibrosis to Monitor Cough With a Wearable Device
This study is open to adults aged 18 years and older who have pulmonary fibrosis with or without a known cause (or other forms of pulmonary fibrosis).
- Trial name
- NCT05670587
- Testing
- A wearable cough monitoring device, the Strados Labs RESPᵀᴹ sensor, with an accompanying mobile application (App) for data collection
- Where
- 13 sites in United States, Belgium and 2 more
- Volunteers
- 53 people
- Sponsor
- Boehringer Ingelheim
Renal Interstitial Fibrosis
Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients
Recently, early biomarkers of renal interstitial fibrosis have been identified, amongst them de novo expression of vimentin by tubular epithelial cells, which is an intermediate filament, and the translocation of beta-catenin…
- Trial name
- CERTITEM (NCT01079143)
- Testing
- Certican®, Neoral, Myfortic
- Where
- 23 sites in France
- Volunteers
- 194 people
- Sponsor
- Novartis Pharmaceuticals
Idiopathic Pulmonary Fibrosis
IPF Italian Observational Study (FIBRONET) in Idiopathic Pulmonary Fibrosis
The purpose of the present study is to evaluate the characteristics, management and clinical course of patients with IPF as treated under real-world in Italian Pulmonary Centres, in terms of symptoms, lung function and exercise…
- Trial name
- NCT02803580
- Where
- 18 sites in Italy
- Volunteers
- 209 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
The main purpose of this study was to see how GLPG1690 works together with your current standard treatment on your lung function and IPF disease in general.
- Trial name
- ISABELA1 (NCT03711162)
- Testing
- GLPG1690
- Where
- 132 sites in United States, Australia and 13 more
- Volunteers
- 525 people
- Sponsor
- Lakefront Biotherapeutics NV
Dementia, Chronic Disease
Project to Improve Communication About Serious Illness--Hospital Study: Comparative Effectiveness Trial (Trial 2)
The objective of this protocol is to test the effectiveness of a Jumpstart intervention on patient-centered outcomes for patients with chronic illness by ensuring that they receive care that is concordant with their goals over…
- Conditions
- Dementia, Chronic Disease, Neoplasm Metastasis, Lung Neoplasms
- Trial name
- PICSI-H (NCT04283994)
- Testing
- Survey-based Patient/Clinician Jumpstart, EHR-based Clinician Jumpstart
- Where
- 3 sites in United States
- Volunteers
- 756 people
- Sponsor
- University of Washington
Idiopathic Pulmonary Fibrosis, Acute Fatal Form
Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Acute exacerbations (AE) are a dreaded manifestation of idiopathic pulmonary fibrosis (IPF) that presents with rapidly worsening respiratory function over days to weeks.
- Trial name
- STRIVE-IPF (NCT03286556)
- Testing
- Autoantibody Reductive Therapy, Treatment as Usual (TAU)
- Where
- 7 sites in United States
- Volunteers
- 82 people
- Sponsor
- University of Alabama at Birmingham
Idiopathic Pulmonary Fibrosis
RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients
This study will be divided into 2 parts. Part 1 is a randomized, double-blind, single centre, placebo-controlled, single ascending dose (SAD) phase I study designed to assess the safety, tolerability, PK and PD (Pharmacodynamic)…
- Trial name
- NCT02257177
- Testing
- Inhaled TD139
- Where
- 5 sites in United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Galecto Biotech AB
Emphysema, Chronic Obstructive Pulmonary Disease (COPD)
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
The purpose of this research study is to learn about the safety of transplanting lungs obtained from non-heart-beating donors (NHBDs) that have been ventilated (attached to a breathing machine or ventilator to deliver oxygen) and…
- Conditions
- Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis
- Trial name
- NCT01615484
- Testing
- Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™, STEEN Solution™
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of North Carolina, Chapel Hill
Lung Diseases, Interstitial, Systemic Sclerosis
Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis
The purpose of this study is to look at whether bortezomib, mycophenolate or the combination of both is better to treat scarring of the lung caused by Systemic Sclerosis.
- Conditions
- Lung Diseases, Interstitial, Systemic Sclerosis, Scleroderma
- Trial name
- NCT02370693
- Testing
- Bortezomib, Mycophenolate mofetil
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Northwestern University
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Families-At-risk for Interstitial Lung Disease Study
The interstitial lung diseases (ILDs) are a family of closely related lung conditions characterized by alveolar inflammation, injury, and fibrosis not due to infection or neoplasia.
- Trial name
- FAR-ILD (NCT03641742)
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Columbia University
Chronic Obstructive Pulmonary Disease, Pulmonary Fibrosis
Using Health-related Quality of Life (HRQL) in Routine Clinical Care
The objective of this study is to assess the effects of using HRQL measures in the clinical care of pre- and post-lung transplant patients.
- Conditions
- Chronic Obstructive Pulmonary Disease, Pulmonary Fibrosis, Pulmonary Hypertension, Cystic Fibrosis
- Trial name
- NCT00457301
- Testing
- HUI score card
- Where
- Canada
- Volunteers
- 213 people
- Sponsor
- University of Alberta
Idiopathic Pulmonary Fibrosis
A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination
The primary objective of this study is to investigate the effect of steady state pirfenidone on the pharmacokinetics of nintedanib and its metabolites following oral administration of 2403 mg/day pirfenidone and to investigate…
- Trial name
- NCT02606877
- Testing
- nintedanib, pirfenidone
- Where
- 9 sites in United Kingdom
- Volunteers
- 37 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Post Marketing Surveillance of Nintedanib in Indian Patients With Idiopathic Pulmonary Fibrosis
This is an active surveillance study to monitor the real world safety of nintedanib in Indian patients with Idiopathic Pulmonary Fibrosis.
- Trial name
- NCT03047031
- Testing
- Nintedanib, Pirfenidone
- Where
- 8 sites in India
- Volunteers
- 21 people
- Sponsor
- Boehringer Ingelheim
Lung Cancer, Radiation Pneumonitis
Mitigation of Radiation Pneumonitis and Fibrosis
This project will test the effect of enalapril to mitigate the lung damage that can occur as a side effect of radiation therapy for lung cancer or other intrathoracic cancers.
- Trial name
- NCT01754909
- Testing
- Enalapril
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- VA Office of Research and Development
Idiopathic Pulmonary Fibrosis
Safety and PK Study of BIBF 1120 in Japanese Patients With IPF
To investigate safety of BIBF 1120 in Japanese patients with idiopathic pulmonary fibrosis (IPF), with and without pirfenidone background treatment.
- Trial name
- NCT01136174
- Testing
- BIBF 1120
- Where
- 8 sites in Japan
- Volunteers
- 50 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
This is a Phase 3 trial to evaluate the efficacy and safety of 30 milligrams (mg)/kilogram (kg) intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in participants with IPF.
- Trial name
- NCT03955146
- Testing
- Pamrevlumab
- Where
- 125 sites in United States, Argentina and 7 more
- Volunteers
- 393 people
- Sponsor
- Kyntra Bio
Idiopathic Pulmonary Fibrosis
Telenursing and Remote Monitoring in Idiopathic Pulmonary Fibrosis (IPF)
Numerous studies show that remote monitoring and/or telenursing improves outcomes for patients especially those with chronic diseases.
- Trial name
- NCT03562247
- Testing
- Usual Care of IPF, Telenursing, Telenursing and Remote Monitoring
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Vanderbilt University Medical Center
Idiopathic Pulmonary Fibrosis
Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)
The primary objectives of this study are to determine the effect of simtuzumab (GS-6624) on progression-free survival (PFS) as determined by either a categorical decline in forced vital capacity (FVC) or all-cause mortality, in…
- Trial name
- RAINIER (NCT01769196)
- Testing
- Simtuzumab
- Where
- 175 sites in United States, Australia and 12 more
- Volunteers
- 544 people
- Sponsor
- Gilead Sciences
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
Adults 40 years of age and older with idiopathic pulmonary fibrosis (IPF) or 18 years and older with progressive pulmonary fibrosis (PPF) can participate in this study. Only people who have a chronic cough can take part.
- Trial name
- NCT06360094
- Testing
- BI 1839100
- Where
- 99 sites in United States, Australia and 22 more
- Volunteers
- 85 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis, Hypoxemia
Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF
This study is a randomized, double-blind, placebo-controlled trial in which eligible IPF subjects will be randomized to receive GBT440 or Placebo orally daily.
- Trial name
- NCT02846324
- Testing
- GBT440
- Where
- 12 sites in United States
- Volunteers
- 39 people
- Sponsor
- Global Blood Therapeutics